表紙:ジェネリック医薬品市場:2024-2034年
市場調査レポート
商品コード
1447777

ジェネリック医薬品市場:2024-2034年

Generic Drugs Market Report 2024-2034

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 357 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=206.60円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ジェネリック医薬品市場:2024-2034年
出版日: 2024年03月04日
発行: Visiongain Reports Ltd.
ページ情報: 英文 357 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のジェネリック医薬品の市場規模は、2034年にかけてCAGR 5.3%で成長すると予測されています。

高齢者人口の増加とジェネリック医薬品の手頃な価格が業界の成長を後押し:

ジェネリック医薬品市場は、高齢者人口の増加やジェネリック医薬品のコスト負担の軽さ、有効性といった主な要因によって大きく牽引されると予想されています。世界の人口構造が高齢化へとシフトするにつれ、慢性疾患の有病率が高まり、長期的な治療が必要となっています。ジェネリック医薬品は、先発医薬品と同等の治療効果を持ち、費用対効果に優れていることから、高齢者のヘルスケアニーズを満たす重要なソリューションとして注目されています。ジェネリック医薬品の手頃な価格は、高齢者がしばしば直面する経済的制約に合致しており、普及を促進しています。政府や医療システムは、ジェネリック医薬品の経済的メリットや利用しやすさを認識しており、さらなる市場成長を促進する政策やイニシアチブを支援する見通しです。

当レポートでは、世界のジェネリック医薬品の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 ジェネリック医薬品市場の分析:タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • シンプルジェネリック
  • 特殊ジェネリック
  • バイオシミラー
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第5章 ジェネリック医薬品市場の分析:処方タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 処方箋
  • OTC
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第6章 ジェネリック医薬品市場の分析:適応症別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 中枢神経系(CNS)
  • 腫瘍
  • 感染症
  • 心血管疾患
  • 消化器疾患
  • 筋骨格系疾患
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第7章 ジェネリック医薬品市場の分析:薬剤クラス別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 抗生物質
  • 抗ヒスタミン薬
  • 鎮痛剤
  • 降圧剤
  • 抗糖尿病薬
  • 解熱剤
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第8章 ジェネリック医薬品市場の分析:投与経路別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 経口
  • 非経口
  • 局所
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第9章 ジェネリック医薬品市場の分析:流通チャネル別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第10章 ジェネリック医薬品市場の分析:地域別

  • 主要調査結果
  • 市場規模の推移・予測

第11章 北米のジェネリック医薬品市場の分析

第12章 欧州のジェネリック医薬品市場の分析

第13章 アジア太平洋のジェネリック医薬品市場の分析

第14章 ラテンアメリカのジェネリック医薬品市場の分析

第15章 中東・アフリカのジェネリック医薬品市場の分析

第16章 企業プロファイル

  • 競合情勢
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Lupin
  • Alkem Laboratories Ltd.
  • Cipla Inc.
  • Biocon
  • Aurobindo Pharma
  • Endo International plc
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.

第17章 総論・推奨事項

  • Visiongainによる総論
  • 参入企業への推奨事項
図表

List of Tables

  • Table 1 Generic Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
  • Table 2 Patent Expiration
  • Table 3 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4 Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 8 Simple Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 9 Specialty Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 10 Biosimilars Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 11 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 12 Prescription Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 13 Over-the-Counter (OTC) Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 14 Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 15 Central Nervous System (CNS) Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 16 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 17 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 18 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 19 Gastrointestinal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 20 Musculoskeletal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 21 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 22 Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 23 Antibiotics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 24 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 25 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 26 Antihypertensive Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 Antidiabetic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 28 Antipyretic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 29 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 31 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 32 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 33 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 35 Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 36 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 37 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 39 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 Global Generic drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 42 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 44 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 45 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 46 North America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 47 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 48 U.S. Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 49 Canada Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 51 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 52 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 53 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 55 Europe Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 56 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 57 Germany Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 UK Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 59 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 61 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 62 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 63 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 64 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 65 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 66 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 67 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 68 Asia Pacific Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 69 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 70 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 71 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 72 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 73 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 74 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 75 Rest of Asia-Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 76 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 77 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 78 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 79 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 80 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 81 Latin America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 82 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 83 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 84 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 85 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 86 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 87 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 88 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 89 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 90 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 91 MEA Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 92 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 93 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 94 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 95 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 96 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Novartis AG: Product Benchmarking
  • Table 98 Novartis AG: Strategic Outlook
  • Table 99 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 101 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 102 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Viatris Inc.: Product Benchmarking
  • Table 104 Viatris Inc.: Strategic Outlook
  • Table 105 Lupin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Lupin: Product Benchmarking
  • Table 107 Lupin: Strategic Outlook
  • Table 108 Alkem Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 Alkem Laboratories Ltd.: Product Benchmarking
  • Table 110 Alkem Laboratories Ltd.: Strategic Outlook
  • Table 111 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Cipla Inc.: Product Benchmarking
  • Table 113 Cipla Inc.: Strategic Outlook
  • Table 114 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Biocon: Product Benchmarking
  • Table 116 Biocon: Strategic Outlook
  • Table 117 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Aurobindo Pharma: Product Benchmarking
  • Table 119 Aurobindo Pharma: Strategic Outlook
  • Table 120 Endo International plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Endo International plc: Product Benchmarking
  • Table 122 Endo International plc: Strategic Outlook
  • Table 123 Torrent Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Torrent Pharmaceuticals Ltd.: Product Benchmarking
  • Table 125 Amneal Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Amneal Pharmaceuticals LLC: Product Benchmarking
  • Table 127 Amneal Pharmaceuticals LLC: Strategic Outlook
  • Table 128 Dr. Reddy's Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 129 Dr. Reddy's Laboratories Ltd.: Product Benchmarking
  • Table 130 Dr. Reddy's Laboratories Ltd.: Strategic Outlook
  • Table 131 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 132 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 133 Sun Pharmaceutical Industries Ltd.: Strategic Outlook

List of Figures

  • Figure 1 Generic Drugs Market Segmentation
  • Figure 2 Generic Drugs Market by Type: Market Attractiveness Index
  • Figure 3 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 4 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
  • Figure 5 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
  • Figure 6 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
  • Figure 7 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 8 Generic Drugs Market Attractiveness Index by Region
  • Figure 9 Global Generic Drugs Market: Market Dynamics
  • Figure 10 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "V" Shaped Recovery
  • Figure 11 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "U" Shaped Recovery
  • Figure 12 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "W" Shaped Recovery
  • Figure 13 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "L" Shaped Recovery
  • Figure 14 Generic drugs Market: Porter's Five Forces Analysis
  • Figure 15 Generic Drugs Market: PEST Analysis
  • Figure 16 Generic Drugs Market Forecast by Type: Market Attractiveness Index
  • Figure 17 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
  • Figure 18 Generic Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 19 Simple Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 20 Simple Generics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Specialty Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 22 Specialty Generics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Biosimilars Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 24 Biosimilars Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
  • Figure 26 Generic Drugs Market Forecast By Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 27 Generic Drugs Market Share Forecast by Prescription Type, 2024, 2029, 2034 (%)
  • Figure 28 Prescription Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 29 Prescription Generics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Over-the-Counter (OTC) Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 31 Over-the-Counter (OTC) Generics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
  • Figure 33 Generic Drugs Market Forecast By Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 34 Generic Drugs Market Share Forecast by Indication, 2024, 2029, 2034 (%)
  • Figure 35 Central Nervous System (CNS) Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 36 Central Nervous System (CNS) Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Oncology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 38 Oncology Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Infectious Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 40 Infectious Diseases Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 42 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Gastrointestinal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 44 Gastrointestinal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 45 Musculoskeletal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 46 Musculoskeletal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 47 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 48 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 49 Generic Drugs Market Forecast by Drug Class: Market Attractiveness Index
  • Figure 50 Generic Drugs Market Forecast By Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 51 Generic Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
  • Figure 52 Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Antihistamines Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 Antihistamines Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 56 Analgesics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 57 Analgesics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 Antihypertensive Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 59 Antihypertensive Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 60 Antidiabetic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 61 Antidiabetic Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 62 Antipyretic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 63 Antipyretic Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 64 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 65 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 66 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 67 Generic Drugs Market Forecast By Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 68 Generic Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 69 Oral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 70 Oral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 71 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 72 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 73 Topical Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 74 Topical Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 75 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 77 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 78 Generic Drugs Market Forecast By Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 79 Generic Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 80 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 81 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 82 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 83 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 84 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 85 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 86 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 87 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 88 Generic Drugs Market Forecast by Region, 2024 & 2034 (Revenue, CAGR%)
  • Figure 89 Generic Drugs Market Share Forecast by Region 2024, 2029, 2034(%)
  • Figure 90 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 91 North America Generic Drugs Market Attractiveness Index
  • Figure 92 North America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 93 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 North America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 95 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 North America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 97 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 North America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 99 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 North America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 101 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 North America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 103 North America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 North America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
  • Figure 105 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 North America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 107 U.S. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 Canada Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 109 Europe Generic Drugs Market Attractiveness Index
  • Figure 110 Europe Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 111 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 112 Europe Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 113 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 114 Europe Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 115 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 116 Europe Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 117 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 118 Europe Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 119 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 120 Europe Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 121 Europe Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 122 Europe Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
  • Figure 123 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 124 Europe Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 125 Germany Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 126 U.K. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 129 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 130 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 131 Asia Pacific Generic Drugs Market Attractiveness Index
  • Figure 132 Asia Pacific Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 133 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 134 Asia Pacific Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 135 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 136 Asia Pacific Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 137 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 138 Asia Pacific Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 139 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 140 Asia Pacific Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 141 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 142 Asia Pacific Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 143 Asia Pacific Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 144 Asia Pacific Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
  • Figure 145 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 146 Asia Pacific Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 147 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 148 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 149 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 150 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 151 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 152 Rest of Asia Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 153 Latin America Generic Drugs Market Attractiveness Index
  • Figure 154 Latin America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 155 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 156 Latin America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 157 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 158 Latin America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 159 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 160 Latin America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 161 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 162 Latin America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 163 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 164 Latin America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 165 Latin America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 166 Latin America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
  • Figure 167 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 168 Latin America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 169 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 170 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 171 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 172 MEA Generic Drugs Market Attractiveness Index
  • Figure 173 MEA Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 174 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 175 MEA Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 176 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 177 MEA Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
  • Figure 178 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 179 MEA Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 180 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
  • Figure 181 MEA Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
  • Figure 182 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
  • Figure 183 MEA Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
  • Figure 184 MEA Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 185 MEA Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
  • Figure 186 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 187 MEA Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 188 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 189 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 190 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 191 Generic Drugs Market: Company Share Analysis, 2023
  • Figure 192 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 193 Novartis AG: Regional Market Shares, 2022
  • Figure 194 Novartis AG: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 195 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
  • Figure 196 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
  • Figure 197 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 198 Viatris Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 199 Viatris Inc.: Regional Market Shares, 2022
  • Figure 200 Viatris Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 201 Lupin: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 202 Lupin: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 203 Alkem Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 204 Alkem Laboratories Ltd.: Regional Market Shares, 2022
  • Figure 205 Alkem Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 206 Cipla Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 207 Cipla Inc.: Regional Market Shares, 2022
  • Figure 208 Cipla Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 209 Biocon: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 210 Biocon: Segmental Market Shares, 2022
  • Figure 211 Biocon: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 212 Aurobindo Pharma: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 213 Endo International plc: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 214 Endo International plc..: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 215 Torrent Pharmaceuticals Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 216 Torrent Pharmaceuticals Ltd.: Regional Market Shares, 2022
  • Figure 217 Amneal Pharmaceuticals LLC: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 218 Amneal Pharmaceuticals LLC: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 219 Dr. Reddy's Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 220 Dr. Reddy's Laboratories Ltd.: Regional Market Shares, 2022
  • Figure 221 Dr. Reddy's Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 222 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 223 Sun Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
目次
Product Code: PHA1316

The global Generic Drugs market is projected to grow at a CAGR of 5.3% by 2034

The Generic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Geriatric Population and Cost Affordability of Generic Drugs Projected to Boost Industry Growth

The generic drugs market is expected to be significantly driven by key factors such as the rising geriatric population and the cost affordability and effectiveness of generic medications. As the global demographic structure shifts towards an aging population, the prevalence of chronic diseases increases, necessitating long-term treatments. Generic drugs, known for their therapeutic equivalence to brand-name counterparts and cost-effectiveness, emerge as crucial solutions to meet the healthcare needs of the elderly. The affordability of generic drugs aligns with the economic constraints often faced by seniors, fostering widespread adoption. Governments and healthcare systems, recognizing the financial advantages and accessibility benefits of generic drugs, are likely to support policies and initiatives that further propel market growth. The combination of a growing elderly population seeking affordable treatments and the proven effectiveness of generic drugs positions this market to play a pivotal role in addressing healthcare challenges and ensuring broader access to essential medications.

Adverse Effects Associated with Drugs Likely to Challenge Market Growth

Adverse effects associated with drugs are anticipated to pose a substantial challenge for the generic drugs market. While generic medications aim to replicate the therapeutic effects of their brand-name counterparts, the one-size-fits-all approach may not adequately address individual variations in patient response. This lack of individualized formulations raises concerns about potential adverse reactions, as patients may experience side effects or inadequate therapeutic responses. Variability in bioavailability among generic drugs further complicates the scenario, potentially leading to variations in drug concentration levels and subsequent adverse effects. Moreover, differences in inactive ingredients between generic and brand-name drugs may impact tolerability, especially for individuals with allergies or sensitivities, creating a need for standardized formulations. The limited post-market surveillance for generic drugs compared to brand-name counterparts raises challenges in timely identification and management of adverse effects, impacting consumer confidence. Addressing these adverse effects associated with generic drugs requires enhanced regulatory measures, rigorous quality control, and a focus on individualized medicine to ensure the sustained growth and success of the generic drugs market.

What Questions Should You Ask before Buying a Market Research Report?

How is the generic drugs market evolving?

What is driving and restraining the generic drugs market?

How will each generic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each generic drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading generic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

How will the industry evolve during the period between 2024 and 2034? What are the implications of generic drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the generic drugs market?

Where is the generic drugs market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Generic Drugs Market today, and over the next 10 years:

Our 357-page report provides 133 tables, 223 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Generic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising generic drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Type

Simple Generics

Specialty Generics

Biosimilars

Route of Administration

Oral

Parenteral

Topical

Others

Indication

Central Nervous System (CNS)

Oncology

Infectious Diseases

Cardiovascular Diseases

Gastrointestinal Diseases

Musculoskeletal Diseases

Others

Drug Class

Antibiotics

Antihistamines

Analgesics

Antihypertensive

Antidiabetic

Antipyretic

Others

Prescription Type

Prescription Generics

Over-the-Counter (OTC) Generics

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

MEA

GCC Countries

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Generic Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

Alkem Laboratories Ltd.

Amneal Pharmaceuticals LLC

Aurobindo Pharma

Biocon

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Endo International plc

Lupin

Novartis AG

Sun Pharmaceuticals Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Torrent Pharmaceuticals Ltd.

Viatris Inc.

Overall world revenue for Generic Drugs Market, 2024 to 2034 in terms of value the market will surpass US$450.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Generic Drugs Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Generic Drugs Market, 2024 to 2034, with forecasts for type, prescription type, indication, drug class, route of administration, distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Generic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the Generic Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Generic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Generic Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Cost Affordability and Effectiveness of Generic Drugs
      • 3.2.1.2 Strategic Partnerships among Generic Drugs Manufacturers
      • 3.2.1.3 Rise in Geriatric Population
      • 3.2.1.4 Rise in Chronic Disorders
      • 3.2.1.5 Rising Government Initiative to Promote Generic Drugs
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Stringent Government Regulations
      • 3.2.2.2 Brand Loyalty
      • 3.2.2.3 Intellectual Property Lawsuits and Patent Disputes
      • 3.2.2.4 Adverse Effects Associated with the Drugs
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Patent Expiration of Blockbuster Drugs in this Decade
      • 3.2.3.2 Growth of Biologics and Biosimilars
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political
    • 3.5.2 Economical
    • 3.5.3 Social
    • 3.5.4 Technological

4 Generic Drugs Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Generic Drugs Market Size Estimation and Forecast by Type
  • 4.4 Simple Generics
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Specialty Generics
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Biosimilars
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Generic Drugs Market Analysis by Prescription Type

  • 5.1 Key Findings
  • 5.2 Prescription Type Segment: Market Attractiveness Index
  • 5.4 Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 5.5 Prescription Generics
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Over-the-Counter (OTC) Generics
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Generic Drugs Market Analysis by Indication

  • 6.1 Key Findings
  • 6.2 Indication Segment: Market Attractiveness Index
  • 6.4 Generic Drugs Market Size Estimation and Forecast by Indication
  • 6.5 Central Nervous System (CNS)
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Oncology
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Infectious Diseases
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8 Cardiovascular Diseases
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)
  • 6.9 Gastrointestinal Diseases
    • 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.9.2 Market Share by Region, 2024 & 2034 (%)
  • 6.10 Musculoskeletal Diseases
    • 6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.10.2 Market Share by Region, 2024 & 2034 (%)
  • 6.11 Others
    • 6.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.11.2 Market Share by Region, 2024 & 2034 (%)

7 Generic Drugs Market Analysis by Drug Class

  • 7.1 Key Findings
  • 7.2 Drug Class Segment: Market Attractiveness Index
  • 7.4 Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 7.5 Antibiotics
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Antihistamines
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Analgesics
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)
  • 7.8 Antihypertensive
    • 7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.8.2 Market Share by Region, 2024 & 2034 (%)
  • 7.9 Antidiabetic
    • 7.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.9.2 Market Share by Region, 2024 & 2034 (%)
  • 7.10 Antipyretic
    • 7.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.10.2 Market Share by Region, 2024 & 2034 (%)
  • 7.11 Others
    • 7.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.11.2 Market Share by Region, 2024 & 2034 (%)

8 Generic Drugs Market Analysis by Route of Administration

  • 8.1 Key Findings
  • 8.2 Route of Administration Segment: Market Attractiveness Index
  • 8.4 Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 8.5 Oral
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)
  • 8.6 Parenteral
    • 8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.6.2 Market Share by Region, 2024 & 2034 (%)
  • 8.7 Topical
    • 8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.7.2 Market Share by Region, 2024 & 2034 (%)
  • 8.8 Others
    • 8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.8.2 Market Share by Region, 2024 & 2034 (%)

9 Generic Drugs Market Analysis by Distribution Channel

  • 9.1 Key Findings
  • 9.2 Distribution Channel Segment: Market Attractiveness Index
  • 9.4 Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.5 Hospital Pharmacies
    • 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.5.2 Market Share by Region, 2024 & 2034 (%)
  • 9.6 Retail Pharmacies
    • 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.6.2 Market Share by Region, 2024 & 2034 (%)
  • 9.7 Online Pharmacies
    • 9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.7.2 Market Share by Region, 2024 & 2034 (%)
  • 9.8 Others
    • 9.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.8.2 Market Share by Region, 2024 & 2034 (%)

10 Generic Drugs Market Analysis by Region

  • 10.1 Key Findings
  • 10.3 Regional Market Size Estimation and Forecast

11 North America Generic Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Generic Drugs Market Attractiveness Index
  • 11.3 North America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 North America Generic Drugs Market Size Estimation and Forecast by Country
  • 11.5 North America Generic Drugs Market Size Estimation and Forecast by Type
  • 11.6 North America Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.7 North America Generic Drugs Market Size Estimation and Forecast by Indication
  • 11.8 North America Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 11.9 North America Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 11.10 North America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.11 U.S. Generic Drugs Market Analysis
  • 11.12 Canada Generic Drugs Market Analysis

12 Europe Generic Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Generic Drugs Market Attractiveness Index
  • 12.3 Europe Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Europe Generic Drugs Market Size Estimation and Forecast by Country
  • 12.5 Europe Generic Drugs Market Size Estimation and Forecast by Type
  • 12.6 Europe Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.7 Europe Generic Drugs Market Size Estimation and Forecast by Indication
  • 12.8 Europe Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 12.9 Europe Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 12.10 Europe Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.11 Germany Generic Drugs Market Analysis
  • 12.12 UK Generic Drugs Market Analysis
  • 12.13 France Generic Drugs Market Analysis
  • 12.14 Italy Generic Drugs Market Analysis
  • 12.15 Spain Generic Drugs Market Analysis
  • 12.16 Rest of Europe Generic Drugs Market Analysis

13 Asia Pacific Generic Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Generic Drugs Market Attractiveness Index
  • 13.3 Asia Pacific Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Type
  • 13.6 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.7 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Indication
  • 13.8 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 13.9 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 13.10 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.11 Japan Generic Drugs Market Analysis
  • 13.12 China Generic Drugs Market Analysis
  • 13.13 India Generic Drugs Market Analysis
  • 13.14 Australia Generic Drugs Market Analysis
  • 13.15 South Korea Generic Drugs Market Analysis
  • 13.16 Rest of Asia Pacific Generic Drugs Market Analysis

14 Latin America Generic Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Generic Drugs Market Attractiveness Index
  • 14.3 Latin America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 14.4 Latin America Generic Drugs Market Size Estimation and Forecast by Country
  • 14.5 Latin America Generic Drugs Market Size Estimation and Forecast by Type
  • 14.6 Latin America Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.7 Latin America Generic Drugs Market Size Estimation and Forecast by Indication
  • 14.8 Latin America Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 14.9 Latin America Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 14.10 Latin America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 14.11 Brazil Generic Drugs Market Analysis
  • 14.12 Argentina Generic Drugs Market Analysis
  • 14.13 Rest of Latin America Generic Drugs Market Analysis

15 MEA Generic Drugs Market Analysis

  • 15.1 Key Findings
  • 15.2 MEA Generic Drugs Market Attractiveness Index
  • 15.3 MEA Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 15.4 MEA Generic Drugs Market Size Estimation and Forecast by Country
  • 15.5 MEA Generic Drugs Market Size Estimation and Forecast by Type
  • 15.6 MEA Generic Drugs Market Size Estimation and Forecast by Route of Administration
  • 15.7 MEA Generic Drugs Market Size Estimation and Forecast by Indication
  • 15.8 MEA Generic Drugs Market Size Estimation and Forecast by Drug Class
  • 15.9 MEA Generic Drugs Market Size Estimation and Forecast by Prescription Type
  • 15.10 MEA Generic Drugs Market Size Estimation and Forecast by Distribution Channel
  • 15.11 GCC Generic Drugs Market Analysis
  • 15.12 South Africa Generic Drugs Market Analysis
  • 15.13 Rest of MEA Generic Drugs Market Analysis

16 Company Profiles

  • 16.1 Competitive Landscape, 2023
  • 16.2 Novartis AG
    • 16.2.1 Company Snapshot
    • 16.2.2 Company Overview
    • 16.2.3 Financial Analysis
      • 16.2.3.1 Net Revenue, 2018-2022
      • 16.2.3.2 Regional Market Shares, 2022
      • 16.2.3.3 R&D Expense, 2018-2022
    • 16.2.5 Product Benchmarking
    • 16.2.6 Strategic Outlook
  • 16.3 Teva Pharmaceutical Industries Ltd.
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Financial Analysis
      • 16.3.3.1 Revenue, 2018-2022
      • 16.3.3.2 Regional Market Shares, 2022
      • 16.3.3.3 R&D Expense, 2018-2022
    • 16.3.5 Product Benchmarking
    • 16.3.6 Strategic Outlook
  • 16.4 Viatris Inc.
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Revenue, 2018-2022
      • 16.4.3.2 Regional Market Shares, 2022
      • 16.4.3.3 R&D Expense, 2018-2022
    • 16.4.5 Product Benchmarking
    • 16.4.6 Strategic Outlook
  • 16.5 Lupin
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Revenue, 2018-2022
      • 16.5.3.2 R&D Expense, 2018-2022
    • 16.5.5 Product Benchmarking
    • 16.5.6 Strategic Outlook
  • 16.6 Alkem Laboratories Ltd.
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2018-2022
      • 16.6.3.2 Regional Market Shares, 2022
      • 16.6.3.3 R&D Expense, 2018-2022
    • 16.6.4 Product Benchmarking
    • 16.6.5 Strategic Outlook
  • 16.7 Cipla Inc.
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Revenue, 2018-2022
      • 16.7.3.2 Regional Market Shares, 2022
      • 16.7.3.3 R&D Expense, 2018-2022
    • 16.7.5 Product Benchmarking
    • 16.7.6 Strategic Outlook
  • 16.8 Biocon
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Financial Analysis
      • 16.8.3.1 Revenue, 2018-2022
      • 16.8.3.2 Segmental Market Shares, 2022
      • 16.8.3.3 R&D Expense, 2018-2022
    • 16.8.5 Product Benchmarking
    • 16.8.6 Strategic Outlook
  • 16.9 Aurobindo Pharma
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Financial Analysis
      • 16.9.3.1 Revenue, 2018-2022
    • 16.9.4 Product Benchmarking
    • 16.9.5 Strategic Outlook
  • 16.10 Endo International plc
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Revenue, 2018-2022
      • 16.10.3.2 R&D Expense, 2018-2022
    • 16.10.4 Product Benchmarking
    • 16.10.5 Strategic Outlook
  • 16.11 Torrent Pharmaceuticals Ltd.
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Revenue, 2018-2022
      • 16.11.3.2 Regional Market Shares, 2022
    • 16.11.4 Product Benchmarking
  • 16.12 Amneal Pharmaceuticals LLC
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Financial Analysis
      • 16.12.3.1 Revenue, 2018-2022
      • 16.12.3.2 R&D Expense, 2018-2022
    • 16.12.4 Product Benchmarking
    • 16.12.5 Strategic Outlook
  • 16.13 Dr. Reddy's Laboratories Ltd.
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Financial Analysis
      • 16.13.3.1 Revenue, 2018-2022
      • 16.13.3.2 Regional Market Shares, 2022
      • 16.13.3.3 R&D Expense, 2018-2022
    • 16.13.4 Product Benchmarking
    • 16.13.5 Strategic Outlook
  • 16.14 Sun Pharmaceutical Industries Ltd.
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Financial Analysis
      • 16.14.3.1 Revenue, 2018-2022
      • 16.14.3.2 R&D Expense, 2018-2022
    • 16.14.4 Product Benchmarking
    • 16.14.5 Strategic Outlook

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players